Clinical trial · no report yet · Phase 2
NCT04468061
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- NCT04468061 ↗
- Recruiting
- Dana-Farber Cancer Institute
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 4 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer; Triple Negative Breast Cancer; PD-L1 Negative
- Interventions
- Sacituzumab Govitecan; Pembrolizumab
- Arms
- Sacituzumab Govitecan + Pembrolizumab · Experimental
- Sacituzumab Govitecan · Experimental
- Retreatment · Experimental
- Enrollment
- 110 (estimated)
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- Dana-Farber Cancer Institute with Gilead Sciences, Merck Sharp & Dohme LLC
- Start
- Jul 20, 2020
- Primary completion
- Apr 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04468061 · updated Apr 29, 2026
Publications
linked from the registry- Kwapisz D. Sacituzumab Govitecan-hziy in Breast Cancer. Am J Clin Oncol. 2022 Jul 1;45(7):279-285. doi: 10.1097/COC.0000000000000919. Epub 2022 May 12. PubMed 35728046